Diffuse Large B-cell Lymphoma (DLBCL)
Showing 1 - 25 of 31
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Diffuse Large B-cell Lymphoma (DLBCL)
- Odronextamab
- +5 more
-
Westbury, New YorkClinical Research Alliance Inc
Oct 13, 2023
Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per
Not yet recruiting
- Chronic Lymphocytic Leukemia (CLL)
- +5 more
- Routine care as per site standard.
- (no location specified)
Sep 15, 2023
Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing
Recruiting
- Relapsed or Refractory B-cell Lymphoma
- +6 more
-
Beijing, ChinaBeijing Cancer Hospital
Feb 6, 2023
Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,
Suspended
- Burkitt Lymphoma
- +4 more
- Rituximab
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Worldwide (CTL019)
Completed
- Diffuse Large B-cell Lymphoma (DLBCL)
- Tisagenlecleucel
- Lymphodepleting chemotherapy
-
San Francisco, California
- +25 more
Jan 27, 2023
DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Active, not recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- +4 more
- EPOCH
- Rituximab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
DLBCL (DLBCL) Trial (Glofitamab, Obinutuzumab, Tocilizumab)
Recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Glofitamab
- +6 more
-
Pembroke Pines, Florida
- +3 more
Jan 23, 2023
Relapsed or Refractory (R/R) Follicular Lymphoma (FL), DLBCL (DLBCL) Trial (Odronextamab)
Available
- Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
- Diffuse Large B-Cell Lymphoma (DLBCL)
- (no location specified)
Nov 8, 2022
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Lanzhou (Zanubrutinib)
Not yet recruiting
- Diffuse Large B-cell Lymphoma (DLBCL)
-
Lanzhou, Gansu, ChinaThe First Hospital of Lanzhou University
Oct 23, 2022
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) Trial in United States (voruciclib
Recruiting
- Follicular Lymphoma (FL)
- +6 more
- voruciclib monotherapy
- voruciclib and venetoclax
-
Duarte, California
- +10 more
Aug 10, 2022
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM) Trial in United States
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- +6 more
-
Duarte, California
- +10 more
Jul 14, 2022
Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma
Completed
- Diffuse Large B-cell Lymphoma (DLBCL)
- CAR-T
- Allo-HSCT cohort
-
East Hanover, New JerseyNovartis Investigative Site
Jun 29, 2022
CAR T Cells Real World Evidence Study Based on French Hospital
Completed
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Acute Lymphoblastic Leukemia (ALL)
- KYMRIAH
- YESCARTA
-
East Hanover, New JerseyNovartis Investigative Site
Jun 29, 2022
All Malignancies, Advanced Malignancies, Hematologic Malignancy Trial in Spain, United States (Tazemetostat, Itraconazole,
Active, not recruiting
- All Malignancies
- +11 more
- Tazemetostat
- +2 more
-
Encinitas, California
- +9 more
May 20, 2022
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Münster (L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab)
Active, not recruiting
- Diffuse Large B-cell Lymphoma (DLBCL)
- L19-IL2 - Ph I
- +2 more
-
Münster, GermanyMünster University Hospital
Apr 19, 2022
Non Hodgkin Lymphoma (NHL), Diffuse Large B-cell Lymphoma (DLBCL) Trial in United States (rituximab, prednisone, Geriatric
Active, not recruiting
- Non Hodgkin Lymphoma (NHL)
- Diffuse Large B-cell Lymphoma (DLBCL)
- rituximab
- +2 more
-
Basking Ridge, New Jersey
- +7 more
Mar 9, 2022
DLBCL (DLBCL) Trial (Tisagenlecleucel)
Withdrawn
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Tisagenlecleucel
- (no location specified)
Feb 25, 2022
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma
Recruiting
- Diffuse Large B-cell Lymphoma (DLBCL)
- +2 more
- leukapheresis
- +3 more
-
Omaha, Nebraska
- +13 more
Jan 21, 2022
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL) Trial in Switzerland, United
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- +6 more
- ME-401
- +2 more
-
Tucson, Arizona
- +23 more
Dec 14, 2021
Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) Trial in Seoul (CRC01,
Recruiting
- Relapsed Large B-cell Lymphoma
- +5 more
- CRC01
- +2 more
-
Seoul, Korea, Republic ofSamsung Medical Center
Apr 29, 2021
CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) Trial
Not yet recruiting
- CD5+ Relapsed/Refractory Hematopoietic Malignancies
- +5 more
- CT125A cells
- Cyclophosphamide, fludarabine
- (no location specified)
Feb 19, 2021
Study to Evaluate Effectiveness and Safety of Polatuzumab
Unknown status
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Polatuzumab Vedotin-Piiq
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Nov 10, 2020